{"id":"mc0518","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"MC0518 inhibits histone deacetylase enzymes, leading to increased histone acetylation and altered gene expression in hematopoietic cells. This mechanism promotes differentiation of myelodysplastic cells and induces apoptosis, reducing abnormal cell proliferation. The drug is designed to restore normal hematopoietic differentiation in MDS patients.","oneSentence":"MC0518 is a histone deacetylase (HDAC) inhibitor that promotes differentiation and apoptosis of myelodysplastic syndrome cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:20:23.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Myelodysplastic syndrome (MDS)"}]},"trialDetails":[{"nctId":"NCT06075706","phase":"PHASE2","title":"Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"medac GmbH","startDate":"2023-11-13","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":48},{"nctId":"NCT04629833","phase":"PHASE3","title":"Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy","status":"RECRUITING","sponsor":"medac GmbH","startDate":"2021-08-16","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":210}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MC0518","genericName":"MC0518","companyName":"medac GmbH","companyId":"medac-gmbh","modality":"Biologic","firstApprovalDate":"","aiSummary":"MC0518 is a histone deacetylase (HDAC) inhibitor that promotes differentiation and apoptosis of myelodysplastic syndrome cells. Used for Myelodysplastic syndrome (MDS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}